These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 2514053

  • 1. GnRH agonist administration in polycystic ovary syndrome.
    Buckler HM, Phillips SE, Kovacs GT, Burger HG, Healy DL.
    Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
    [Abstract] [Full Text] [Related]

  • 2. Ovulation induction with human menopausal gonadotropin versus follicle-stimulating hormone after pituitary suppression by gonadotropin releasing hormone agonist in polycystic ovary disease. A cross-over study.
    Fulghesu AM, Lanzone A, Guida C, Nicoletti MC, Rossi P, Le Donne M, Caruso A, Mancuso S.
    J Reprod Med; 1992 Oct; 37(10):834-40. PubMed ID: 1479563
    [Abstract] [Full Text] [Related]

  • 3. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A, Fulghesu AM, Spina MA, Apa R, Menini E, Caruso A, Mancuso S.
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [Abstract] [Full Text] [Related]

  • 4. Serum inhibin levels in polycystic ovary syndrome: basal levels and response to luteinizing hormone-releasing hormone agonist and exogenous gonadotropin administration.
    Buckler HM, McLachlan RI, MacLachlan VB, Healy DL, Burger HG.
    J Clin Endocrinol Metab; 1988 Apr; 66(4):798-803. PubMed ID: 3126215
    [Abstract] [Full Text] [Related]

  • 5. Luteal function following ovulation induction in polycystic ovary syndrome patients using exogenous gonadotrophins in combination with a gonadotrophin-releasing hormone agonist.
    Donderwinkel PF, Schoot DC, Pache TD, de Jong FH, Hop WC, Fauser BC.
    Hum Reprod; 1993 Dec; 8(12):2027-32. PubMed ID: 8150898
    [Abstract] [Full Text] [Related]

  • 6. [Ovulation induction with pulsatile gonadotropin-releasing hormone and continuous human menopausal gonadotropin in polycystic ovarian disease].
    Kuroda G.
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar 20; 63(3):247-59. PubMed ID: 3111899
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of low dose purified FSH in ovulation induction following pituitary desensitization in polycystic ovarian syndrome.
    Buckler HM, Critchley HO, Cantrill JA, Shalet SM, Anderson DC, Robertson WR.
    Clin Endocrinol (Oxf); 1993 Feb 20; 38(2):209-17. PubMed ID: 8435902
    [Abstract] [Full Text] [Related]

  • 8. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N.
    J Clin Endocrinol Metab; 1986 Dec 20; 63(6):1379-85. PubMed ID: 2946711
    [Abstract] [Full Text] [Related]

  • 9. Long-acting gonadotrophin releasing hormone agonist implant causes variable duration of suppression of ovarian steroid and inhibin secretion.
    Fraser HM, Haining R, Cowen GM, Sandow J, Smith KB, Smith SK.
    Clin Endocrinol (Oxf); 1992 Jan 20; 36(1):97-104. PubMed ID: 1559303
    [Abstract] [Full Text] [Related]

  • 10. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S, Gülekli B, Turhan NO, Ozakşit G, Odabaşi AR, Oral H, Ozcan U, Gökmen O.
    Gynecol Endocrinol; 1995 Jun 20; 9(2):91-6. PubMed ID: 7502695
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A, Faure N, Labrie F, Fazekas AT.
    Fertil Steril; 1985 Jun 20; 43(6):868-77. PubMed ID: 3158551
    [Abstract] [Full Text] [Related]

  • 12. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H, Jung C, Taubert HD.
    Clin Endocrinol (Oxf); 1984 Aug 20; 21(2):179-88. PubMed ID: 6432376
    [Abstract] [Full Text] [Related]

  • 13. Failure to improve ovarian response by combined gonadotropin-releasing hormone agonist and gonadotropin therapy.
    Bider D, Kokia E, Lipitz S, Blankstein J, Mashiach S, Serr DM, Ben-Rafael Z.
    Gynecol Obstet Invest; 1990 Aug 20; 29(3):192-6. PubMed ID: 2113505
    [Abstract] [Full Text] [Related]

  • 14. Patterns of serum FSH, LH and hCG after i.m. or i.v. administration of hMG during pituitary suppression.
    Duijkers IJ, Hollanders HM, Willemsen WN, de Leeuw R, Vemer HM.
    Int J Fertil Menopausal Stud; 1995 Aug 20; 40(2):86-91. PubMed ID: 7599664
    [Abstract] [Full Text] [Related]

  • 15. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
    Hohmann FP, Laven JS, Mulders AG, Oberyé JJ, Mannaerts BM, de Jong FH, Fauser BC.
    J Endocrinol Invest; 2005 Dec 20; 28(11):990-7. PubMed ID: 16483177
    [Abstract] [Full Text] [Related]

  • 16. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D, Steingold K, Cedars M, Lu JK, Meldrum DR, Judd HL, Chang RJ.
    J Clin Endocrinol Metab; 1989 Jun 20; 68(6):1111-7. PubMed ID: 2524501
    [Abstract] [Full Text] [Related]

  • 17. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J, De Vits A, Joostens M, Van Royen E.
    Hum Reprod; 1995 Jan 20; 10(1):56-62. PubMed ID: 7745071
    [Abstract] [Full Text] [Related]

  • 18. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A, Faure N, Bastide A.
    Fertil Steril; 1987 Jan 20; 47(1):60-6. PubMed ID: 2947818
    [Abstract] [Full Text] [Related]

  • 19. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N, Lemay A.
    Clin Endocrinol (Oxf); 1987 Dec 20; 27(6):703-13. PubMed ID: 3138052
    [Abstract] [Full Text] [Related]

  • 20. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec 20; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.